Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,676 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Alectinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Spirometry test, Levalbuterol; Device · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypoxemic Respiratory Failure
Interventions: HFNC flow set at patient peak tidal inspiratory flow, HFNC flow set at 1.33 times of patient peak tidal inspiratory flow, HFNC flow set at 1.67 times of patient peak tidal inspiratory flow, HFNC flow set at 2 times of patient peak tidal inspiratory flow; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions: cisplatin, dimesna, paclitaxel; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Buffalo, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort); Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 80
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib, Sildenafil, Bosentan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tampa, Florida • Weston, Florida • Mineola, New York

Conditions: Malignant Mesothelioma
Interventions: epirubicin hydrochloride, gemcitabine hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 24
States / cities: Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 21 more

Conditions: Obesity, Obstructive Sleep Apnea
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Northridge, California • Rolling Hills Estates, California • Brandon, Florida + 10 more

Conditions: Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
Interventions: Abemaciclib,; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Chemotherapy, Pembrolizumab, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 566
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more

Conditions: Asthma
Interventions: Placebo, BI 54903, Fluticasone propionate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, iNO; Drug
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Charleston, South Carolina

Conditions: Chronic Graft-versus-host-disease
Interventions: Belumosudil (KD025); Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 12 Years and older
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 30 more

Conditions: Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions: Motexafin Gadolinium; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Favipiravir, Placebo comparator; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 148
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more

Conditions: Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Interventions: Radiation therapy; Radiation
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Houston, Texas • Milwaukee, Wisconsin

Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: FT836, Cetuximab, Trastuzumab; Drug
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: zileuton, azathioprine/prednisone; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 35 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Bronchitis
Interventions: RejuvenAir System, Sham Control Procedure; Device
Lead sponsor: CSA Medical, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Mountain View, California • Sacramento, California + 22 more

Conditions: Carcinoma, Non- Small Cell Lung
Interventions: Durvalumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Daytona Beach, Florida + 7 more

Conditions: Coronavirus, COVID, ARDS, Cytokine Storm, Cytokine Release Syndrome
Interventions: SNDX-6352, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • The Bronx, New York

Conditions: COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions: Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C; Drug · Dietary Supplement
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Ventura, California

Conditions: Chronic Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Cystitis, Interstitial, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions: Psychosocial Treatment, Pelvic Floor Physical Therapy; Behavioral · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Franklin, Tennessee

Search by objective public record fields.

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

COPD Assessment and Management Bundle Versus Usual Care

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Correlation of Peak Tidal Inspiratory Flow Measured Before and After Extubation in Adult Patients With Hypoxemia

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

RejuvenAir® System Trial for COPD With Chronic Bronchitis

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

Trial of Combination Therapy to Treat COVID-19 Infection

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment